Home > Products > All > DOXOrubicin Hydrochloride Injection, USP*
Product Image
Please see full prescribing and safety information, including boxed warning, for DOXOrubicin vials.

Available in:

  • 50 mg per 25 mL single-dose vials
  • 200 mg per 100 mL multi-dose vials

Benefits:

  • AP Rated
  • Preservative-free
  • Not made with natural rubber latex

Downloads:

PreventIV

DOXOrubicin Hydrochloride Injection, USP*

Brand Name Equivalent: ADRIAMYCIN® (ADRIAMYCIN is a registered trademark of Hikma Pharmaceuticals.)
Therapeutic Category: Antineoplastic

PreventIV Measures® Features:

  • Easy-to-read drug name and dosage strength to aid in identifying the right product
  • Bar codes included on the vial and carton for ease of scanning
  • Unique label design to help products stand out on the shelf
  • Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
NDC
#25021		 Description Strength Fill
Volume 		Concentration Container
Size 		Closure Unit
of Sale
207-25 Glass Vial 50 mg 25 mL 2 mg per mL 30 mL 20 mm 1
207-51 Glass Vial 200 mg 100 mL 2 mg per mL 100 mL 20 mm 1
WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning.
  • Cardiomyopathy: Myocardial damage can occur with doxorubicin hydrochloride with incidences from 1% to 20% for cumulative doses from 300 mg/m2 to 500 mg/m2 when doxorubicin hydrochloride is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with doxorubicin hydrochloride. (5.1)
  • Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin hydrochloride. (5.2)
  • Extravasation and Tissue Necrosis: Extravasation of doxorubicin hydrochloride can result in severe local tissue injury and necrosis requiring wide excision and skin grafting. Immediately terminate the drug, and apply ice to the affected area. (5.3)
  • Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur. (5.4)